| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 07/12/2005 | US6916823 Method of treatment of dopamine-related dysfunction |
| 07/12/2005 | US6916820 Neurotrophic substituted pyrimidines |
| 07/12/2005 | US6916819 Benzimidazole and pyridylimidazole derivatives |
| 07/12/2005 | US6916818 Nitrogen compounds such as 1-(1-Naphthalenesulfonyl)-3-(octa-hydro-4-quinolizinyl)-1H-5-azaindole, used as serotonin receptor antagonists for prophylaxis of psychological disorders |
| 07/12/2005 | US6916814 Methods of treating cytokine mediated diseases |
| 07/12/2005 | US6916811 Adenosine A2a receptor antagonists |
| 07/12/2005 | US6916807 Triaryl-oxy-aryl-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors |
| 07/12/2005 | US6916798 Inhibitors of glycogen synthase kinase-3 (GSK-3), a serine/threonine protein kinase; for treatment and prevention of diabetes and Alzheimer's disease |
| 07/12/2005 | US6916485 Mixture of protein, hydrophilic polymer, group 1a alkyl sulfate and sugar |
| 07/12/2005 | CA2341739C Quinolin-2-one derivatives useful as anticancer agents |
| 07/12/2005 | CA2323008C Pharmaceutically active compounds |
| 07/12/2005 | CA2303309C Synergistic analgesic combination of opioid analgesic and cyclooxygenase-2 inhibitor |
| 07/12/2005 | CA2298142C Soya extract, process for its preparation and pharmaceutical composition |
| 07/12/2005 | CA2244912C Novel substituted cyclic amino acids as pharmaceutical agents |
| 07/12/2005 | CA2240327C Method for effecting changes in the central nervous system by administration of igf-i or igf-ii |
| 07/12/2005 | CA2195370C A method of separating the racemate of tramadol |
| 07/12/2005 | CA2137525C Isopropyl 2-methoxyethyl 4-(2-chloro-3-cyano-phenyl)-1,4-dihydro-2,6-dimethyl-pyridine-3,5-dicarboxylate |
| 07/12/2005 | CA2105867C Novel imidazole derivatives, their preparation and therapeutic applications |
| 07/07/2005 | WO2005061684A1 Fat composition |
| 07/07/2005 | WO2005061495A1 Nicotinic acetylcholine receptor ligands |
| 07/07/2005 | WO2005061494A1 Nicotinic acetylcholine receptor ligands |
| 07/07/2005 | WO2005061484A1 1,2,3,4-tetrahydroisoquinoline derivatives, preparations thereof and uses thereof |
| 07/07/2005 | WO2005061454A1 Agent or method for treatment for severe aphasia in chronic-stage cerebrovascular disorder |
| 07/07/2005 | WO2005037839A8 Norcantharidin derivative compounds, method for the production thereof, compositions containing said compounds and the use thereof |
| 07/07/2005 | WO2005037783A3 Use of tricyclic compounds as glycine transport inhibitors |
| 07/07/2005 | WO2005037782A3 Derivatives of n-[phenyl(alkylpiperidine-2-yl)methyl]benzamide, preparation method thereof and application of same in therapeutics |
| 07/07/2005 | WO2004022560A9 Pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| 07/07/2005 | US20050148664 therapy of NF-kappaB mediated diseases; mitochondrial diseases; transplantation medicine |
| 07/07/2005 | US20050148650 protein kinase B activating agents for preventing or treating depression, PTSD, Parkinson's disease, Alzheimer's diseases, and the like; comprises for e.g. [1] 2-[2,2,4,6,7-pentamethyl-3-(4-methylphenyl)-2,3-dihydro-1-benzofuran-5-yl]isoindoline |
| 07/07/2005 | US20050148642 Metabotropic glutamate receptor antagonists containing a saturated oxygen- or nitrogen-containing ring or a cycloalkyl ring, e.g., N-methyl-N-neopentyl-6-[(oxetan-3-ylamino)methyl]thiazolo[3,2-a]benzimidazole-2-carboxamide, having excellent oral activity, used especially for treating neuropathic pain |
| 07/07/2005 | US20050148641 2-Methylthiazolidine-2,4-dicarboxylic acid and salts thereof for the treatment of neurodegenerative diseases |
| 07/07/2005 | US20050148637 Neurotrophic low molecular weight ketones and tioester compounds for treatment of nervous system disorders and neurodegenerative conditions |
| 07/07/2005 | US20050148636 Useful aroyl pyrrole heteroaryl methanones and methanols |
| 07/07/2005 | US20050148625 Use of estrogen antagonists and estrogen agonists inhibiting pathological conditions |
| 07/07/2005 | US20050148624 Enzyme inhibitors with isoquinolinone structures |
| 07/07/2005 | US20050148621 Acetylcholinesterase dual inhibitors |
| 07/07/2005 | US20050148619 Sulfonamido ether substituted imidazoquinolines |
| 07/07/2005 | US20050148617 Drugs for eating disorders and treating obesity or anxiety with G protein |
| 07/07/2005 | US20050148611 Compounds capable of activating cholinergic receptors |
| 07/07/2005 | US20050148604 Increase the intracellular cAMP level and further inhibit the activation of T cells; allergic diseases, inflammatory or immunological diseases |
| 07/07/2005 | US20050148591 Tartrate salts of 5,8,14-triazatetracyclo [10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaen and pharmaceutical compositions thereof |
| 07/07/2005 | US20050148582 N-[1-butyl-4-piperidinylmethyl[3,4-dihydro-2 oxazino[3,2-a indole-10 carboxamide as drugs with Cahpo4 or Ca3/po4/2 fillers or binders for use in treatment of irritable bowel syndrome, urinry incontience or arrhythmias |
| 07/07/2005 | US20050148580 Non-opioid analgesics for chronic and acute pain; 1-[1-(p-phenylbenzyl)-4-piperidinyl]-2,1,3-benzothiadiazol-2,2-dione; modulation of the opioid and ORL I receptors; agonist or antagonist activity at the CNS mu, delta and kappa receptors greater than morphine |
| 07/07/2005 | US20050148575 (Di)Azepino[5,4,3-cd]benzothiophenes; poly(ADP-ribose) polymerase (PARP) and glycohydrolase (PARG) inhibitor; antiinflammatory; protects cells, tissue and organs against the ill-effects of reactive free radicals and nitric oxide, and damage following focal ischemia and reperfusion injury |
| 07/07/2005 | US20050148550 Substituted C-furan-2-yl-methylamine and C-thiophen-2-yl-methylamine compounds |
| 07/07/2005 | US20050148549 Compositions and methods for inhibition of phospholipase a2 mediated inflammation |
| 07/07/2005 | US20050148510 Protein with a hedgehog N-terminal domain covalently bound to a polypeptide with 10-30 hydrophobic amino acids, C 8-24 aliphatic, saturated or unsaturated hydrocarbon residues, or a hydrophobic thio group |
| 07/07/2005 | US20050148062 Transgenic microorganisms comprising apoptosis associated genes for use as tools in identifying modulators for prevention and treatment of cell proliferative disorders |
| 07/07/2005 | US20050148058 Protein stabilization |
| 07/07/2005 | US20050148014 Regulation of human P2Y1-like G protein-coupled receptor |
| 07/07/2005 | US20050148013 Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof |
| 07/07/2005 | US20050147674 A tablet or capsule prepared from a mixture of crystalline escitalopram oxalate having a median particle size of > 40 mu m and excipients; large particle size for use in direct compression; controlled crystallization from solution to avoid granulation and drying steps; binder-and lactose-free |
| 07/07/2005 | US20050147670 Oral disintegrating dosage forms |
| 07/07/2005 | US20050147665 Consisting of eicosapentaenoic acid or derivative, vitamin B 12, folic acid, at a maximum daily dose of 5 mg, and vitamin B6, at a maximum daily dose of 20 mg, and optionally at least one antioxidant; treatment of psychiatric disorders; schizophrenia, Alzheimer's disease, dementia, Parkinson's disease |
| 07/07/2005 | US20050147613 using bispecific antibodies comprising an antibody having binding specificity which confers the ability to cross the blood-brain barrier, and a second antibody conferring the ability to bind to beta -amyloid epitopes, used for the treatment of Alzheimer's disease or Down's syndrome |
| 07/07/2005 | US20050147583 Carbamylation to form a water soluble prodrug that has a biologically active agent linked to a water soluble non-immunogenic polymer; a hydrolyzing through carbamate bond; drug delivery; no enzymes or catalysts needed for release of acitve agent |
| 07/07/2005 | US20050147567 highly dispersible mixture of drugs and dipeptides or tripeptides, in the form of liquids, aerosols or powders, administered by inhalation |
| 07/07/2005 | DE10105038B4 Tripeptid-Derivate für die Behandlung von postläsionalen Krankheiten des Nervensystems Tripeptide derivatives for the treatment of postlesional diseases of the nervous system |
| 07/07/2005 | CA2800228A1 Small peptides for the treatment of alzheimer's disease and other beta-amyloid protein fibrillogenesis disorders |
| 07/07/2005 | CA2550847A1 Nicotinic acetylcholine receptor ligands |
| 07/07/2005 | CA2550844A1 Nicotinic acetylcholine receptor ligands |
| 07/07/2005 | CA2550843A1 Novel phenylalanine derivatives |
| 07/07/2005 | CA2550655A1 Nicotinic acetylcholine receptor ligands |
| 07/07/2005 | CA2550643A1 1,2,3,4-tetrahydroisoquinoline derivatives, preparations thereof and uses thereof |
| 07/07/2005 | CA2550215A1 Diphenylazetidinone derivates possessing cholesterol absorption inhibitory activity |
| 07/07/2005 | CA2549956A1 Nogo-a neutralising immunoglobulins for treatment of neurological diseases |
| 07/07/2005 | CA2549863A1 Use of relaxin as adjuvant in the differentiation of stem cells for the reconstruction of tissues |
| 07/07/2005 | CA2549429A1 Fat composition |
| 07/07/2005 | CA2549308A1 Aralkyl and aralkylidene heterocyclic lactams with affinity for 5-ht1 receptors |
| 07/07/2005 | CA2549007A1 Substituted (4-aminocyclohexen-1-yl)phenyl and (4-aminocyclohexen-1-yl)pyridinyl compounds as 5-ht1f agonists |
| 07/07/2005 | CA2548917A1 Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression |
| 07/07/2005 | CA2548824A1 Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs |
| 07/07/2005 | CA2548410A1 Diphenylazetidinone derivates processing cholesterol absorption inhibitory activity |
| 07/07/2005 | CA2548304A1 Selective norepinephrine reuptake inhibitors for the treatment of hot flashes, impulse control disorders and personality change due to a general medical condition |
| 07/07/2005 | CA2547338A1 Composition and methods for modulating cns activity |
| 07/07/2005 | CA2546943A1 Novel compounds |
| 07/07/2005 | CA2543578A1 Genes commonly regulated by different classes of antidepressants |
| 07/07/2005 | CA2540230A1 Aminopyridine-derivatives as inductible no-synthase inhibitors |
| 07/06/2005 | EP1550719A1 Methods and medicament for inhibition the expression of a defined gene |
| 07/06/2005 | EP1550655A1 Bicyclic intermediates |
| 07/06/2005 | EP1550456A2 Use of botulinum toxin in the treatment of burn pain |
| 07/06/2005 | EP1550454A1 Extracorporeal photopheresis in combination with anti-TNF treatment |
| 07/06/2005 | EP1550443A1 Composition against stress-related diseases |
| 07/06/2005 | EP1550442A1 Composition for preventing/treating the expression of clinical symptom in disease caused by mitochondrial dysfunction |
| 07/06/2005 | EP1549756A2 Recombinatant mutants of rhabdovirus and methods of use thereof |
| 07/06/2005 | EP1549740A2 Oligodendrocyte production from multipotent neural stem cells |
| 07/06/2005 | EP1549660A2 RNA INTERFERENCE MEDIATED INHIBITION OF GRB2-ASSOCIATED BINDING PROTEIN 2 (GAB2) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 07/06/2005 | EP1549651A1 Kinase inhibitors |
| 07/06/2005 | EP1549650A1 Substituted c-imidazo[1,2-a]pyridin-3-yl-methylamines |
| 07/06/2005 | EP1549649A1 Process for preparing haloalkyl pyrimidines |
| 07/06/2005 | EP1549640A2 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)pyrrolidine-3-carboxylates as edg receptor agonists |
| 07/06/2005 | EP1549639A1 Sulphonamide derivatives as antipsychotic agents |
| 07/06/2005 | EP1549637A1 1- (indol-3-yl)carbonyl piperazine derivatives |
| 07/06/2005 | EP1549636A1 Imidazol-1-ylmethyl pyridazine derivatives |
| 07/06/2005 | EP1549634A1 Novel substituted indoles |
| 07/06/2005 | EP1549633A1 Nicotine-containing, controlled release composition and method |
| 07/06/2005 | EP1549632A1 Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions |
| 07/06/2005 | EP1549624A2 Inhibitors of fatty acid amide hydrolase |
| 07/06/2005 | EP1549619A1 6-amino-1h-indazole and 4-aminobenzofuran compounds as phosphodiesterase 4 inhibitors |
| 07/06/2005 | EP1549615A1 Naphthamide derivatives and their use |